Nuveen’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-154,424
| Closed | -$1.54M | – | 3283 |
|
|
2025
Q2 | $1.54M | Sell |
154,424
-149,226
| -49% | -$1.2M | ﹤0.01% | 2417 |
|
|
2025
Q1 | $1.81M | Buy |
303,650
+243,249
| +403% | +$1.79M | ﹤0.01% | 2377 |
|
|
2024
Q4 | $464K | Sell |
60,401
-96,930
| -62% | -$833K | ﹤0.01% | 3010 |
|
|
2024
Q3 | $1.61M | Sell |
157,331
-200,840
| -56% | -$3.06M | ﹤0.01% | 2525 |
|
|
2024
Q2 | $5.32M | Sell |
358,171
-12,930
| -3% | -$185K | ﹤0.01% | 1926 |
|
|
2024
Q1 | $5.06M | Buy |
371,101
+177,700
| +92% | +$1.94M | ﹤0.01% | 1990 |
|
|
2023
Q4 | $2.12M | Buy |
193,401
+133,501
| +223% | +$1.32M | ﹤0.01% | 2387 |
|
|
2023
Q3 | $656K | Sell |
59,900
-15,811
| -21% | -$202K | ﹤0.01% | 2748 |
|
|
2023
Q2 | $1M | Sell |
75,711
-21,571
| -22% | -$308K | ﹤0.01% | 2660 |
|
|
2023
Q1 | $1.32M | Buy |
97,282
+7,854
| +9% | +$141K | ﹤0.01% | 2498 |
|
|
2022
Q4 | $1.75M | Sell |
89,428
-10,676
| -11% | -$209K | ﹤0.01% | 2450 |
|
|
2022
Q3 | $1.91M | Sell |
100,104
-129,173
| -56% | -$2.98M | ﹤0.01% | 2424 |
|
|
2022
Q2 | $4.72M | Buy |
229,277
+25,363
| +12% | +$602K | ﹤0.01% | 1985 |
|
|
2022
Q1 | $6.71M | Buy |
203,914
+14,566
| +8% | +$529K | ﹤0.01% | 1898 |
|
|
2021
Q4 | $7.11M | Buy |
189,348
+82,799
| +78% | +$2.76M | ﹤0.01% | 1896 |
|
|
2021
Q3 | $3.06M | Sell |
106,549
-1,763
| -2% | -$46.1K | ﹤0.01% | 2471 |
|
|
2021
Q2 | $2.78M | Sell |
108,312
-17,460
| -14% | -$416K | ﹤0.01% | 2552 |
|
|
2021
Q1 | $4.3M | Buy |
125,772
+70,784
| +129% | +$2.56M | ﹤0.01% | 2234 |
|
|
2020
Q4 | $1.86M | Buy |
54,988
+32,361
| +143% | +$857K | ﹤0.01% | 2552 |
|
|
2020
Q3 | $558K | Buy |
+22,627
| New | +$609K | ﹤0.01% | 2918 |
|
Other funds holding ITOS
Nuveen's ITOS Position: Q3 2025 in Review
Nuveen sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 154,424 shares — an estimated $1.54M sold.
Nuveen first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $7.11M in Q4 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Nuveen reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Nuveen sold 154,424 iTeos Therapeutics shares in Q3 2025, an estimated $1.54M.
- Nuveen first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
- Nuveen's iTeos Therapeutics position peaked at $7.11M in Q4 2021.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Nuveen's 13F filing for Q3 2025, filed 12 Nov 2025.